Speculation Over Moderna Vaccine Deal With Tata, Wockhardt
COVAX Obligation Could Be A Driver
Executive Summary
Moderna is speculated to be in talks with Indian firms, including Wockhardt and a Tata group company, for manufacturing and/or marketing its COVID-19 vaccine. A deal in India could help the company meet its obligation to supply COVAX but Moderna is likely to choose its partner carefully.
You may also be interested in...
Eight COVID-19 Vaccines Approved In India In 2021, mRNA Addition Awaited
While an mRNA vaccine is still missing, 2021 saw Indian companies strike alliances, battle legal action and gain funding while the regulator played a crucial enabling role in the run up to the approval of eight COVID-19 vaccines from zero in 2020.
Tracing Cipla’s Interest In Vaccines, Potential For Tie-Up With Moderna
Cipla is no novice in the vaccines segment and a potential link up for Moderna’s mRNA COVID-19 vaccine or with other firms could add an important lever in the 80-plus year-old Indian firm’s overall strategic thrust. Management has all along maintained a positive tone for coronavirus vaccine alliances.
Moderna COVID-19 Boosters Show Preclinical Efficacy Versus South African Variant
While preclinical data show boosters to MRNA-1273 can reduce the threat of viral variants, the biotech also told investors it sees no link between its vaccine and thrombotic episodes.